Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic Malignancy & Solid Tumor Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for WT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | WT1 Full-Length & Zinc Finger Domain Recombinant Proteins (including ±KTS isoforms) and WT1 Peptide-HLA Complexes. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. | View WT1 Products |
| Gene Delivery | WT1 Promise-ORF / Lentivirus with isoform options (±KTS, ±Exon 5). Full-length ORF for stable cell lines. Codon-optimized. | View WT1 Products |
| Benchmark Ab | Anti-WT1/HLA Complex TCRm Control (recombinant positive control) and Anti-WT1 research-grade monoclonal antibody (clone C-terminal) for IHC/Flow/SPR/ChIP. Sequence verified. | View WT1 Products |
| Validator | WT1 siRNA Set (three unique target sites) for knockdown verification and specificity checks. | View WT1 Products |
| Related Target A | HLA-A – Essential MHC class I presentation partner for WT1 peptides. | View HLA-A Products |
| Related Target B | CD3E – Key component for WT1-targeting T-cell engagers (TCE). | View CD3E Products |
| Related Target C | MEN1 (Menin) – Epigenetic axis partner in MLL-rearranged leukemia; co-targeting strategy. | View MEN1 Products |
| Related Target D | PRAME – Intracellular tumor antigen for multi-antigen T-cell therapy development. | View PRAME Products |
| Related Target E | BCL2 – Anti-apoptotic pathway partner in AML; synergistic inhibition studies. | View BCL2 Products |
| Related Target F | IL3RA (CD123) – Synergistic AML target for dual-targeting strategies. | View IL3RA Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Peptide-MHC specificity screening | Recombinant pMHC complexes expressed in HEK293 with precise peptide loading and >95% purity; comprehensive homolog and alternative peptide-MHC panels verified by mass spec. |
| TCR off-target toxicity | Pan-zinc finger panel proteins (EGR1, SP1, ZNF family) and homology panel available for cross-reactivity testing. |
| Isoform-specific binder development (±KTS, ±Exon 5 splice variants) | Isoform-specific protein panels with sequence-verified N-/C-termini and native glycosylation. |
| Drug resistance mutations (e.g., R394W, R396C) | Mutant protein panels available for escape mechanism studies; sequence verified. |
| Intracellular target biophysical screening | HEK293-expressed WT1 full-length and zinc finger domain proteins (>95% purity, endotoxin <1 EU/µg) for SPR/ITC. |
| Lack of controls | Clinical benchmark antibodies (TCRm) and WT1 siRNA set included. |
| False positives in cell assays | Valid WT1 lentivirus and siRNA for specific target regulation. |
| Target engagement for antisense or small molecule | Full-length and truncated mutant proteins for DNA competition binding and PPI studies. |
Live WT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
WT1 (Wilms tumor 1) is an intracellular transcription factor highly expressed in acute myeloid leukemia (AML), malignant pleural mesothelioma, and many solid tumors. Because it is intracellular, traditional antibodies cannot directly target it. The current R&D landscape is dominated by cancer vaccines (e.g., Sellas Life Sciences' Galinpepimut-S in Phase III for AML), TCR-T cell therapies (TCR2 Therapeutics, Allogene, TScan Therapeutics), and TCR-mimic (TCRm) bispecific antibodies (Eureka Therapeutics, Roche). As first-generation therapies advance, the next wave focuses on broader HLA-type compatibility (beyond HLA-A*02:01), overcoming immunosuppressive solid tumor microenvironments, and combination regimens with checkpoint inhibitors or targeted agents (e.g., Menin inhibitors). The development of isoform-specific and mutation-specific reagents is critical for affinity tuning and off-target toxicity screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cancer Vaccine (Peptide/DC-Based) | Sellas Life Sciences, Otsuka | AML, Malignant Pleural Mesothelioma | Immunogenicity & Epitope Binding (Need high-purity WT1 isoform proteins) |
| TCR-T / TCR-NK Cell Therapy | TCR2 Therapeutics, Allogene, TScan Therapeutics, Immatics | AML, Solid Tumors | TCR Specificity Screening (Need WT1 peptide/HLA complex and mutant controls) |
| TCR-mimic (TCRm) Bispecifics | Eureka Therapeutics, Roche | Hepatocellular Carcinoma, AML, Ovarian Cancer | Peptide-MHC Selectivity & T-cell Activation Assay (Need native glycosylated pMHC and CD3E proteins) |
| Small Molecule / Peptide Inhibitor | Academic / Biotech Consortiums | Nephroblastoma, Desmoplastic Small Round Cell Tumor | Zinc Finger Domain Binding (Need full-length & truncated mutant proteins) |
| Antisense Oligonucleotides | Sarepta, Ionis (exploratory) | Nephroblastoma | Target Engagement Assays (Need WT1 knockdown validation tools) |